Vanda Pharmaceuticals (VNDA) Capital Expenditures (2011 - 2026)
Vanda Pharmaceuticals (VNDA) posted Capital Expenditures of $221000.0 for Q1 2026, up 116.67% sequentially from $102000.0 in Q4 2025, and down 49.31% YoY from $436000.0 in Q1 2025.
Vanda Pharmaceuticals (VNDA) Capital Expenditures (2011 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Capital Expenditures for 16 years, with the latest figure at $221000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 49.31% year-over-year to $221000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $783000.0 (down 14.8% YoY) and the FY2025 annual result came in at $998000.0, up 103.67% from the prior year.
- Capital Expenditures rose to $221000.0 in Q1 2026 per VNDA's latest filing, from $102000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $436000.0 in Q1 2025 and troughed at $7000.0 in Q1 2024.
- A 5-year average of $163000.0 and a median of $161000.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 86.27% in 2024, then surged 6128.57% in 2025.
- Over 5 years, Capital Expenditures stood at $263000.0 in 2022, then dropped by 3.8% to $253000.0 in 2023, then slipped by 15.42% to $214000.0 in 2024, then plunged by 52.34% to $102000.0 in 2025, then soared by 116.67% to $221000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $221000.0, $102000.0, and $161000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 190,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190,000.00 |
| Jun 30, 2026 | 190,000.00 |
| Mar 31, 2026 | 221,000.00 |
| Mar 31, 2026 | 221,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 108,000.00 |
| Jun 30, 2024 | 108,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |